Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest Expenses (2016 - 2025)

Collegium Pharmaceutical (COLL) has 9 years of Interest Expenses data on record, last reported at $19.3 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 14.84% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $82.3 million, up 11.27%, while the annual FY2025 figure was $82.3 million, 11.27% up from the prior year.
  • Interest Expenses reached $19.3 million in Q4 2025 per COLL's latest filing, down from $21.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $22.7 million in Q4 2024 and bottomed at $4.8 million in Q4 2021.
  • Average Interest Expenses over 5 years is $16.2 million, with a median of $19.2 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: plummeted 38.52% in 2021, then skyrocketed 332.52% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $4.8 million in 2021, then skyrocketed by 332.52% to $20.6 million in 2022, then dropped by 6.29% to $19.3 million in 2023, then increased by 17.49% to $22.7 million in 2024, then decreased by 14.84% to $19.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $19.3 million in Q4 2025, $21.8 million in Q3 2025, and $20.5 million in Q2 2025.